The plausibility battleground at the EPO
Servickuz / Shutterstock.com
Is the grant of a reasonable scope for antibody-related inventions at the European Patent Office a phenomenon of the past? Joachim Wachenfeld and Florian Grasser of Vossius & Partner report.
The invention of the antibody hybridoma technology by Nobel prize winners Georges Köhler and César Milstein in 1975 paved the way to the development of therapeutic antibodies.
The first therapeutic monoclonal antibody obtained market approval in the US in 1986. Since then the market value of therapeutic antibodies has grown to approximately $115.2 billion in 2018 and is expected to reach $300 billion in 2025.
Along with this development, the number of patent applications seeking protection for therapeutic antibodies at the European Patent Office (EPO) has constantly grown and is growing further.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
EPO, therapeutic antibodies, inventions, Vossius & Partner, prior art, CDRs, framework regions, Boards of Appeal, US Patent and Trademark Office